ReNeuron Company Profile

21:48 EDT 24th March 2018 | BioPortfolio

ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.


Europoint Centre , 5-11 Lavington Street
United Kingdom


Phone: 0207 928 1720
Fax: 0207 261 0268

News Articles [12 Associated News Articles listed on BioPortfolio]

ReNeuron Group (RENE) - Biblical aspirations

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s interim results for the six months to 30 September 2017 showcased a crucial juncture in the company’s ...

ReNeuron Group (RENE) - Consolidation confusion?

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s recent 100 for 1 share consolidation was a benign and cosmetic ‘tidy up’ of its historical capit...

ReNeuron's CTX cells play a part in positive artificial nerve tissue study

This is the first time ReNeuron's CTX cells have been combined with an engineered support to guide nerve repair

ReNeuron pleased to secure podium presentation for stroke data at US conference

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) tells Proactive positive long-term data on their CTX cell therapy for stroke has been presented at the American Heart Association International Str...

Big batches, big margins: Reneuron on off-the-shelf stem cells

Difficulty in scaling-up autologous cell therapies means margins are low says Reneuron, which is focused on off-the-shelf stem cell products.

ReNeuron presents positive data for CTX cell therapy candidate

Cell-based therapeutics developer ReNeuron Group announced on Friday that positive long-term data from the Phase II clinical trial - PISCES II -of its CTX cell therapy candidate for stroke disabili...

ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE) updates Proactive on their phase II clinical study treating stroke patients with its CTX stem cells. Hunt says the positive r...

'Lots to look forward to' as ReNeuron gets go-ahead for phase IIb stroke trial

Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE),  tells Proactive they've been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for s...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


ReNeuron stem cell transplantation biotechnology for brain cell therapeutics to promote recovery of function.

ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. We are also leveraging our ste...

More Information about "ReNeuron" on BioPortfolio

We have published hundreds of ReNeuron news stories on BioPortfolio along with dozens of ReNeuron Clinical Trials and PubMed Articles about ReNeuron for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ReNeuron Companies in our database. You can also find out about relevant ReNeuron Drugs and Medications on this site too.

Quick Search


Relevant Topics

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record